Medivir Transfers HIV Drug Alovudine License To Beijing Mefuvir
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Sweden-based Medivir AB will transfer its license and intellectual property for its HIV drug Alovudine (MIV-310) to subsidiary Beijing Mefuvir, Medivir announced Dec. 21